recording an average of over 7 days of heart monitoring. Despite US FDA approval, the Zio Patch has met slow acceptance possibly due to reimbursement hurdles. Explanations for the slow acceptance ...

Zio XT has been recommended by NICE as an option for people with suspected cardiac arrhythmias who would benefit from ECG monitoring for longer than 24 hours, as a lighter, discreet alternative to ...

The stock of iRhythm went from $30 to $285 over a similar stretch, as its Zio ECG-patch won most of the medical market for the long-term monitoring that determines if heart flutters actually are AFib.